Xenetic Biosciences, Inc. (XBIO) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-2.57 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.57 vs est $-2.57 (beat +0%). 2025: actual $-1.58 vs est $-2.04 (beat +22.5%). Analyst accuracy: 85%.
XBIO Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Xenetic Biosciences, Inc. in the past 3 months
EPS Estimates — XBIO
85%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.57
vs Est –$2.57
▼ 0.0% off
2025
Actual –$1.58
vs Est –$2.04
▲ 29.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — XBIO
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.003B
vs Est $0.003B
▲ 0.0% off
2025
Actual $0.003B
vs Est $0.003B
▲ 16.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
